Testosterone depletion is the keystone for therapy of patients metastic prostatic carcinoma. Our objective was to investigate Leydig cell function and testosterone levels after withdrawal of long-term endocrine treatment in patients with prostatic carcinoma. Thirteen patients with prostatic carcinoma, previously treated with oestrogens for at least 4 y, were stimulated with 5000 IU human chorionic gonadotrophin (hCG). The stimulation was performed 3 ± 6 y after cessation of the oestrogen therapy. Serum concentrations of testosterone, luteinizing hormone (LH) and follicle stimulating hormone (FSH) were measured before and 24 and 48 h after hCG stimulation. Before hCG stimulation all patients had low serum testosterone concentrations (mean 2.0 AE 0.2 nmolal) and 24 and 48 h after hCG stimulation the values had not signi®cantly increased (mean 2.4 AE 0.2 and 2.5 AE 1.1 nmolal, respectively). LH and FSH were within or above the normal range before but after hCG stimulation the values signi®cantly increased. In conclusion, the study shows that the Leydig cells were unable to respond to hCG stimulation more than 3 y after cessation of oestrogen therapy. The Leydig cell function seems to be irreversibly impaired by long-term oestrogen treatment.
Introduction
Oestrogen treatment for prostate carcinoma has been used since Huggins and Hodges in 1941 demonstrated that patients with metastatic prostate cancer receiving oestrogen therapy showed clinical improvement, particularly reduced bone pain from metastases and a reduced serum acid phosphatase level. It is well accepted that testosterone level reduction in prostatic tissue is the main reason for the tumour response. 1 Suppression of serum testosterone concentration to castrate levels is recommended when using oestrogen therapy. 2 To achieve castrate levels of testosterone, high doses of oestrogen therapy are needed; 3 however, several studies have demonstrated that patients with prostate carcinoma treated with oestrogens may develop cardiac andaor thromboembolic complications which consequently lead to withdrawal of oestrogen therapy. 4 ± 6 Patients having such complications during oestrogen therapy, are usually offered orchidectomy after discontinuing oestrogen therapy in order to maintain low serum testosterone concentrations. Tomic et al has shown in patients treated with oestrogens for more than 3 y that there is no signi®cant increase in serum testosterone concentration following cessation of the oestrogen therapy. 7 Also, other studies have indicated that long-term treatment with oestrogen could cause irreversible damage to the Leydig cell function. 8, 9 These ®ndings suggest that oestrogen has a direct or indirect effect on the Leydig cells.
In order to elucidate whether long-term oestrogen therapy had caused irreversible and long-standing damages on the Leydig cell function itself, patients previously treated long-term were stimulated with hCG in vivo and the hormonal response was measured.
Patients and methods
The subjects were 13 patients with morphologically veri®ed prostate carcinoma in stage T1 ± T3, Nx. Their mean age at the time of hCG stimulation was 76.3 y (range 64 ± 90 y). The patients were primarily treated with oestrogens for a mean time of 7.4 y (range 4.1 ± 12.7 y). The oestrogen treatment included ethinyloestradiol (ETIVEX 1 ) given orally, 50 mg three times daily in combination with polyoestradiol phosphate (ESTRADURIN 1 ) intramuscularly 160 mg once a month during the ®rst 3 months and thereafter 80 mg once a month. The oestrogen therapy was withdrawn due to cardiac andaor thromboembolic complications in all patients. The interval between withdrawal of oestrogens and the hCG stimulation was between 3 and 6 y. None of the studied patients had bone metastasis at the time of oestrogen cessation or during the follow-up period until the hCG stimulation. After informed consent to attend in this stimulation test the patients were given 5000 IU hCG (PREGNYL 1 ) subcutaneously as a single dose between 8 and 10 a.m. Immediately before the hCG injection, and 24 and 48 h after the hCG stimulation serum samples for testosterone, LH and FSH were collected. The serum concentrations of testosterone, LH and FSH were measured by radioimmunoassy methods. 10 ± 12 The normal level for testosterone is ! 13 nmolal, for LH 4 ± 22 ual and for FSH 3 ± 28 ual. During the follow-up period until the hCG stimulation all patients had been followed up every 6 ± 12 months with measurement of acid phosphatase, rectal palpation of the prostate and if necessary with a bone scan.
Statistical methods
Wilcoxon's paired test was used for statistical analyses. The values are expressed as the mean value AE s.e.m. (standard error of the mean).
Results
In 13 patients serum testosterone concentrations remained low (mean 2.0 AE 0.2 nmolal). 3 ± 6 y after cessation of long-term oestrogen treatment. The mean serum levels of testosterone, LH and FSH before and after hCG stimulation are shown in Figure 1 and Table 1 . At 24 and 48 h after hCG stimulation a slight but not signi®cant increase in serum testosterone concentrations was recorded (mean 2.4 AE 0.2 nmolal, and 2.5 AE 1.1 nmolal, respectively).
Before hCG stimulation, serum concentrations of LH were within or above the normal range (mean 31.4 AE 7.5 ual) and increased (P`0.0001) signi®cantly 24 and 48 h after hCG stimulation (mean 94.7 AE 14.1 ual, and 76 AE 13.5 ual, respectively; Table 1 ). Compared with the 
Discussion
At the time when the patients in the present study were initially diagnosed, the standard active treatment for prostate carcinoma was either oestrogen therapy or orchidectomy. Many patients were treated with oestrogen therapy with or without evidence of metastatic spread. The patients included in the present study had no metastatic spread at diagnosis and when the long-term oestrogen therapy was withdrawn because of complications. Therefore no other treatment needed to be introduced. After 3 ± 6 y since withdrawal of the oestrogen therapy the serum testosterone concentration still remained low. None of the patients showed any Leydig cell response to hCG stimulation, although a pituitary response was observed. The serum testosterone levels remained low even though high doses of hCG were given. In healthy men between 19 and 90 y it has been shown that serum testosterone concentration increases signi®cantly when high doses of hCG are given. 13 In the present study, in contrast, a lack of testosterone response was shown after long-term oestrogen therapy and at the same time LH and FSH levels signi®cantly increased after hCG stimulation. All our patients responded to the hCG stimulation, indicating that the hypophyseal ± hypothalamus function had remained intact. However, one might suspect an abnormality in the hypothalamic ± pituitary axis since some of the patients before the hCG stimulation had low testosterone levels and concomitant normal LH levels in serum.
Our study showing a lack of testosterone response to hCG stimulation in vivo after previous withdrawal of long-term oestrogen therapy con®rms a previous in vitro study. 14 In that study, testicular tissues obtained at orchidectomy from patients who had been treated with oestrogens for prostatic carcinoma, after stimulation with hCG showed no increase in testosterone concentration in the supernatant. In contrast, testosterone increased in the supernatant of the testicular culture obtained from previously untreated patients. 14 Furthermore, in vivo hCG stimulation of patients on treatment with oestrogens caused no increase in serum testosterone concentration. 15, 16 In a previous study on patients with prostatic carcinoma it was shown that testosterone concentration in serum remained low many years after completion of longterm oestrogen treatment. 4 These results are con®rmed in the present study, showing maintained low testosterone levels 3 ± 6 y after cessation of long-term oestrogen treatment. The hCG stimulation was unable to cause an increase in testosterone concentration in serum. These data clearly indicate that long-term treatment with oestrogens causes irreversible impairment of the Leydig cell function. The lack of hCG effect on the Leydig cell function found in this study might be directly caused by the oestrogens or by indirect damage to the Leydig cells due to long-standing low gonadotropin stimulation. The mechanism of action of oestrogens leading to this permanent impaired Leydig cell function is not known.
Whether other medical treatments such as long-term luteinizing hormone releasing hormone (LHRH) analogs, which cause long term inhibition of testosterone production, also might impair Leydig cell function remains uncertain. 17, 18 With the spiralling costs of hormonal therapy for advanced prostate cancer and the possibility that long-term (2 ± 3 y) therapy with LHRH-agonists plus antiandrogen may lead to irreversible Leydig cell damage, this facilitates the possibility of also dispensing with such therapies. Studies after cessation of such therapies are therefore desirable. Furthermore, investigations of the Leydig cell function using intermittent therapy may also assume a greater importance.
In conclusion, in patients with prostate cancer previously treated long-term with oestrogens, the Leydig cells seen unable to respond to hCG stimulation despite a time interval of 3 y or more after cessation of oestrogen therapy. The Leydig cell function seems to be irreversibly impaired by long-term oestrogen treatment.
